OrthoPediatrics Corp. v. Wishbone Medical, Inc.

CourtDistrict Court, N.D. Indiana
DecidedJuly 31, 2023
Docket3:20-cv-00929
StatusUnknown

This text of OrthoPediatrics Corp. v. Wishbone Medical, Inc. (OrthoPediatrics Corp. v. Wishbone Medical, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Indiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
OrthoPediatrics Corp. v. Wishbone Medical, Inc., (N.D. Ind. 2023).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF INDIANA SOUTH BEND DIVISION

ORTHOPEDIATRICS CORP., et al.,

Plaintiffs,

v. CASE NO. 3:20-CV-929-JD-MGG

WISHBONE MEDICAL, INC., et al.,

Defendants.

OPINION AND ORDER Ripe before the Court is Plaintiffs Orthex, LLC, Orthopediatrics Corp., and Vilex LLC (“Plaintiffs’”) Motion to Compel Document Production from Defendants WishBone Medical, Inc. (“WishBone”) and Nick A. Deeter (collectively “Defendants”), filed on December 2, 2022, in this patent infringement case. For the reasons discussed below, Plaintiffs’ Motion to Compel is granted in part and denied in part. I. FACTUAL BACKGROUND Orthopedic professionals use devices called external fixators to treat patients suffering from broken bones or other bone abnormalities. An external fixator fits around an individual’s limb and often has a certain number of struts that run into the limb and attach to the bone to ensure the bone is positioned for proper healing. In the past, orthopedic professionals had to rely on their own estimations and experience to determine exactly how to position the external fixator and accompanying struts on a limb. With the advent of new technology, patented on April 16, 2019, under patent number 10,258,377 (“the ‘377 Patent” 1), orthopedic professionals can now look at an X- ray, or other photographic image of a patient’s bone, and the fixator apparatus on a

computer screen, use a mouse or other device to inscribe lines and points on the images as needed, and then generate calculations showing the optimal way to position the bones using the external fixator. Plaintiff Orthex LLC, a wholly owned subsidiary of Plaintiff OrthoPediatrics Corp., is the assignee of the ‘377 Patent, and Plaintiff Vilex, a medical device company, is an exclusive licensee. Plaintiffs initiated this patent infringement case on October 30,

2020, alleging that WishBone is—or imminently will be—infringing the ‘377 Patent through the sale, use, and promotion of its Smart Correction External Fixation System (“Smart Correction” or “Accused System”). According to Plaintiffs, Smart Correction copies the process described in the ‘377 Patent.2 II. PROCEDURAL POSTURE

The parties are currently engaged in discovery related to Plaintiffs’ patent infringement claims3 following the Court’s claim construction, or Markman, order entered on October 4, 2022 [DE 118]. A stipulated protective order governs the

1 The ‘377 Patent is entitled “Point and Click Alignment Method for Orthopedic Surgeons, and Surgical and Clinical Accessories and Devices.” [DE 1-4]. 2 Defendant Nick Deeter, a former employee of OrthoPediatrics, is a founding member and current CEO of WishBone. OrthoPediatrics also maintains a breach of contract claim against Mr. Deeter. [See DE 33 at 40; DE 68 at 30]. As the discovery dispute at issue in the instant motion only relates to the infringement claims, no further development of the contract claim is necessary. 3 Count I of Plaintiffs’ operative amended complaint raises a claim for infringement of the ‘377 Patent against WishBone while Count II seeks declaratory judgment that WishBone infringed the ‘377 Patent. [DE 33 at 26, 37]. production, exchange, and designation of confidential and highly-confidential, attorneys’ eyes only materials throughout this action. [DE 108].

Since September 16, 2021, when Plaintiffs served their first 30 requests for production upon Defendants, production of responsive materials has been the source of significant contention among the parties. On November 16, 2021, Defendants served responses to Plaintiffs’ first requests asserting blanket objections to multiple requests on grounds of relevance, overbreadth, lack of specificity, or undue burden. Plaintiffs served their second requests for production on January 21, 2022, with a letter outlining

deficiencies in Defendants’ responses to date and 15 additional requests for production. On February 22, 2022, Defendants responded to Plaintiffs’ second requests raising objections to each request. As discovery continued, the parties jointly sought extension of the discovery deadlines by motion on October 24, 2022. In that motion, the parties reported that

Defendants expected to complete their discovery productions before the middle of November 2022. After the middle of November passed, Plaintiffs still found Defendants’ production incomplete leading them to file the instant Motion to Compel on December 2, 2022, after attempts to resolve the dispute themselves. Alleging superfluous production and technical deficiencies, Plaintiffs contend that Defendants

have stonewalled discovery by withholding or otherwise failing to locate and produce information responsive to their requests for production. Plaintiffs argue that Defendants’ outstanding discovery responses include information critical to their infringement claims, damages theories, and secondary considerations of non- obviousness4.

Defendants, however, argue that the breadth of Plaintiffs’ requests has caused the discovery delays. Defendants contend that Plaintiffs are asking for wholly irrelevant information and have “regularly expanded the breadth of their requests in email exchanges between counsel . . . .” [DE 125 at 5-6]. Defendants also assert that they have been unable to satisfy Plaintiffs’ demands, despite working diligently to do so with at least five supplemental productions in November and December 2022. Without

withdrawing their relevance and overbreadth objections, Defendants also request bifurcation of discovery to avoid potentially unnecessary and burdensome damages- related discovery because they perceive a high probability of prevailing on the infringement claims. Plaintiffs oppose bifurcation and reiterate the continued deficiencies in Defendants’ discovery production. Bifurcation will be addressed first.

III. BIFURCATION Bifurcation may be ordered “[f]or convenience, to avoid prejudice, or to expedite and economize.” Fed. R. Civ. P. 42(b). Bifurcation is the exception, rather than the rule, in patent cases. “A single trial generally tends to lessen the delay, expense, and inconvenience to all concerned.” THK Am., Inc. v. NSK Co., 151 F.R.D. 625, 631 (N.D. Ill.

1993). In deciding whether to grant bifurcation, the Court must consider whether

4 In assessing the obviousness of a patent, courts looks to several factors including “[s]uch secondary considerations as commercial success, long felt but unsolved needs, [and] failure of others.” Days Corp. v. Lippert Components, Inc., CAUSE NO. 3:17CV208-PPS/MGG, CAUSE NO. 3:17CV327-PPS/MGG, 2022 WL 1237433, at *2 (N.D. Ind. Apr. 27, 2022) (citing Graham v. John Deere Co. of Kansas City, 383 U.S. 1, 17–18 (1966). An obviousness analysis would be relevant to an invalidity defense. See 35 U.S.C. § 103. separate trials would prevent prejudice to a party or promote judicial economy. Chlopek v. Fed. Ins. Co., 499 F.3d 692, 700 (7th Cir. 2007); see also, e.g., Saunders v. Metro. Prop.

Mgmt., Inc., 561 F. Supp. 3d 629, 631 (W.D. Va. 2021) (emphasizing the importance of prejudice toward the non-moving party in deciding bifurcation). The moving party has the burden of demonstrating that bifurcation is appropriate based on the circumstances of the case. CDX Liquidating Tr. ex rel. CDX Liquidating Tr. v. Venrock Assocs., 389 B.R. 76, 81 (N.D. Ill. 2008). Ultimately, the Court retains discretion to decide whether to grant or deny bifurcation. Rodriguez v. City of Chicago, 429 F. Supp.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Graham v. John Deere Co. of Kansas City
383 U.S. 1 (Supreme Court, 1966)
Minks v. Polaris Industries, Inc.
546 F.3d 1364 (Federal Circuit, 2008)
Motionless Keyboard Company v. Microsoft Corporation
486 F.3d 1376 (Federal Circuit, 2007)
Invitrogen Corp. v. Biocrest Manufacturing, l.p.
424 F.3d 1374 (Federal Circuit, 2005)
Microsoft Corp. v. i4i Ltd. Partnership
131 S. Ct. 2238 (Supreme Court, 2011)
Panduit Corp. v. Stahlin Bros. Fibre Works, Inc.
575 F.2d 1152 (Sixth Circuit, 1978)
Chlopek v. Federal Insurance
499 F.3d 692 (Seventh Circuit, 2007)
Georgia-Pacific Corp. v. United States Plywood Corp.
318 F. Supp. 1116 (S.D. New York, 1970)
McGrath v. EVEREST NATIONAL INSURANCE COMPANY
625 F. Supp. 2d 660 (N.D. Indiana, 2008)
Star Scientific, Inc. v. R.J. Reynolds Tobacco Co.
655 F.3d 1364 (Federal Circuit, 2011)
Apple Inc. v. Motorola, Inc.
757 F.3d 1286 (Federal Circuit, 2014)
United States v. Jeffrey Parkhurst
865 F.3d 509 (Seventh Circuit, 2017)
01 Communique Laboratory, Inc v. Citrix Online, LLC
889 F.3d 735 (Federal Circuit, 2018)
Ericsson, Inc. v. Harris Corp.
352 F.3d 1369 (Federal Circuit, 2003)
Volkman v. Ryker
736 F.3d 1084 (Seventh Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
OrthoPediatrics Corp. v. Wishbone Medical, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/orthopediatrics-corp-v-wishbone-medical-inc-innd-2023.